Biotechnology company Hopewell Therapeutics has raised $25m in seed financing to accelerate the development of next-generation lipid nanoparticles for targeted delivery of genomic medicines.
Participants in the funding round, which was raised in multiple tranches, include IMO Capital, 5Y Capital, BOPU Capital, WS Investments, Mass Ave Capital and HIKE Capital.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company will use the funds to advance the development of genomic medicines, using its differentiated tissue-targeted lipid nanoparticle (ttLNP) platform.
Hopewell Therapeutics is engaged in discovering, synthesising and developing advanced ttLNPs to provide next-generation genomic medicines.
The development will be advanced through both internal pipeline programmes and external collaborations.
The ttLNP platform can deliver a range of high-impact genomic payloads, including gene editing, siRNA, mRNA, DNA and gene-writing apparatus, to tissues, cells and organs.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHopewell Therapeutics president and CEO Louis Brenner stated: “Hopewell Therapeutics seeks to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body.
“The ground-breaking research and intellectual property in LNP [lipid nanoparticle] design and delivery established by Professor Xu over the last decade provide a solid foundation for Hopewell to develop our own internal pipeline, initially targeting diseases of the lung while concurrently exploring the potential of our ttLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases and neurological disorders.”
